Development and Comparison of Warfarin Dosing Algorithms in Stroke Patients
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: The genes for cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase complex subunit 1 (VKORC1) have been identified as important genetic determinants of warfarin dosing and have been studied. We developed warfarin algorithm for Korean patients with stroke and compared the accuracy of warfarin dose prediction algorithms based on the pharmacogenetics. Materials and Methods: A total of 101 patients on stable maintenance dose of warfarin were enrolled. Warfarin dosing algorithm was developed using multiple linear regression analysis. The performance of all the algorithms was characterized with coefficient of determination, determined by linear regression, and the mean of percent deviation was used to predict doses from the actual dose. In addition, we compared the performance of the algorithms using percentage of predicted dose falling within ±20% of clinicallyobserved doses and dividing the patients into a low-dose group (≤3 mg/day), an intermediate-dose group (3–7 mg/day), and high-dose group (≥7 mg/day). Results: A new developed algorithms including the variables of age, body weight, and CYP2C9 and VKORC1 genotype. Our algorithmaccounted for 51% of variation in the warfarin stable dose, and performed best in predicting dose within 20% of actual dose and intermediate-dose group. Conclusion: Our warfarin dosing algorithm may be useful for Korean patients with stroke. Further studies to elucidate clinical utilityof genotype-guided dosing and find the additional genetic association are necessary.
Abstract
Purpose: The genes for cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase complex subunit 1 (VKORC1) have been identified as important genetic determinants of warfarin dosing and have been studied. We developed warfarin algorithm for Korean patients with stroke and compared the accuracy of warfarin dose prediction algorithms based on the pharmacogenetics. Materials and Methods: A total of 101 patients on stable maintenance dose of warfarin were enrolled. Warfarin dosing algorithm was developed using multiple linear regression analysis. The performance of all the algorithms was characterized with coefficient of determination, determined by linear regression, and the mean of percent deviation was used to predict doses from the actual dose. In addition, we compared the performance of the algorithms using percentage of predicted dose falling within ±20% of clinicallyobserved doses and dividing the patients into a low-dose group (≤3 mg/day), an intermediate-dose group (3–7 mg/day), and high-dose group (≥7 mg/day). Results: A new developed algorithms including the variables of age, body weight, and CYP2C9 and VKORC1 genotype. Our algorithmaccounted for 51% of variation in the warfarin stable dose, and performed best in predicting dose within 20% of actual dose and intermediate-dose group. Conclusion: Our warfarin dosing algorithm may be useful for Korean patients with stroke. Further studies to elucidate clinical utilityof genotype-guided dosing and find the additional genetic association are necessary.
참고문헌 (29)
- Kaminsky LS, "Human P450 metabolism of warfarin", Pharmacol Ther, 73, pp.67~74 (1997)
- Whitlon DS, "Mechanism of coumarin action: significance of vitamin K epoxide reductase inhibition", Biochemistry, 17, pp.1371~1377 (1978)
- Stafford RS, "The underutilization of cardiac medications of proven benefit, 1990 to 2002", J Am Coll Cardiol, 41, pp.56~61 (2003)
- Pirmohamed M, "Warfarin: almost 60 years old and still causing problems", Br J Clin Pharmacol, 62, pp.509~511 (2006)
- Hylek EM, "Risk factors for intracranial hemorrhage in outpatients taking warfarin", Ann Intern Med, 120, pp.897~902 (1994)
- Hylek EM, "An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation", N Engl J Med, 335, pp.540~546 (1996)
- Loebstein R, "Interindividual variability in sensitivity to warfarin--nature or nurture?", Clin Pharmacol Ther, 70, pp.159~164 (2001)
- Scordo MG, "Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population", Pharmacol Res, 50, pp.195~200 (2004)
- Bae JW, "Allele and genotype frequencies of CYP2C9 in a Korean population", Br J Clin Pharmacol, 60, pp.418~422 (2005)
- Lindh JD, "Influence of CYP2C9genotype on warfarin dose requirements--a systematic review and meta-analysis", Eur J Clin Pharmacol, 65, pp.365~375 (2009)
- Kim HS, "Effect of CY-P2C9 and VKORC1 genotypes on early-phase and steady-state warfarin dosing in Korean patients with mechanical heart valve replacement", Pharmacogenet Genomics, 19, pp.103~112 (2009)
- Yang L, "Impact of VKORC1 gene polymorphism on interindividual and interethnic warfarin dosage requirement--a systematic review and meta analysis", Thromb Res, 125, pp.e159~e166 (2010)
- International Warfarin Pharmacogenetics Consortium, "Estimation of the warfarin dose with clinical and pharmacogenetic data", N Engl J Med, 360, pp.753~764 (2009)
- Gage BF, "Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin", Clin Pharmacol Ther, 84, pp.326~331 (2008)
- Sconce EA, "The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen", Blood, 106, pp.2329~2333 (2005)
- Ohno M, "Influence of clinical and genetic factors on warfarin dose requirements among Japanese patients", Eur J Clin Pharmacol, 65, pp.1097~1103 (2009)
- Wadelius M, "The largest prospective warfarin-treated cohort supports genetic forecasting", Blood, 113, pp.784~792 (2009)
- Cho HJ, "Development and comparison of a warfarin-dosing algorithm for Korean patients with atrial fibrillation", Clin Ther, 33, pp.1371~1380 (2011)
- Huang SW, "Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients", Pharmacogenet Genomics, 19, pp.226~234 (2009)
- Anderson JL, "Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation", Circulation, 116, pp.2563~2570 (2007)
- Wu AH, "Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations", Pharmacogenomics, 9, pp.169~178 (2008)
- Yamaguchi T, "Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation:a multicenter, prospective, randomized trial. Japanese Nonvalvular Atrial Fibrillation-Embolism Secondary Prevention Cooperative Study Group", Stroke, 31, pp.817~821 (2000)
- Zhou SF, "Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2", Drug Metab Rev, 42, pp.268~354 (2010)
- Holbrook AM, "Systematic overview of warfarin and its drug and food interactions", Arch Intern Med, 165, pp.1095~1106 (2005)
- Limdi NA, "Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups", Blood, 115, pp.3827~3834 (2010)
- Zhu Y, "Estimation of warfarin maintenance dose based on VKORC1 (-1639 G>A) and CYP2C9 genotypes", Clin Chem, 53, pp.1199~1205 (2007)
- Caraco Y, "CYP2C9 genotype-guided warfarin prescribing enhances the effcacy and safety of anticoagulation: a prospective randomized controlled study", Clin Pharmacol Ther, 83, pp.460~470 (2008)
- Bogousslavsky J, "Ischemic stroke in patients under age 45", Neurol Clin, 10, pp.113~124 (1992)
- Bungard TJ, "Drug interactions involving warfarin: practice tool and practical management tips", Can Pharm J, 144, pp.21.e9~25.e9 (2011)